Table 1 Demographic profile of subjects
From: Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine
| Â | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | ||||
|---|---|---|---|---|---|---|---|---|
Subject 1 | Subject 2 | Subject 3 | Subject 4 | Subject 5 | Subject 6 | Subject 7 | Subject 8 | |
GAP vaccine dose (viable parasites) | 1800 | 1.8×105 | 3×106 | 3×106 | ||||
Age (years) | 40 | 48 | 26 | 19 | 32 | 18 | 29 | 20 |
Sex | Male | Male | Male | Male | Male | Male | Male | Male |
Race | Latin Hispanic | Latin Hispanic | White | Australian Aboriginal | White | White | White | White |
Body mass index (kg/m2) | 23.0 | 27.3 | 18.1 | 21.7 | 26.7 | 23.8 | 26.8 | 23.0 |